Add this topic to your myFT Digest for news straight to your inbox
You select the topic, we deliver the news.
Sample the FT’s top stories for a week
Comments come as Swiss drugmaker reports 4% increase in group sales
Lack of ambition or exercise in prudence?
Efforts follow criticism of drug pricing and access in some of the poorest parts of the world
Swiss pharma group says treatment showed signs of outperforming others
Separating the healthcare unit makes sense. Announcing it now does not
Swiss pharmaceuticals group’s sales rise 4% to SFr37.5bn in nine months
Many experts believe a new type of drug promises to revolutionise treatment
Chief Schwan urges pharma groups to keep innovating to stave off criticism
Outcry over a 5,000% price rise has rattled stocks and hardened opinion for change on pricing models
The same global insight. Faster than ever before on all your devices.